Botulinum Toxin Type A on an Intranasal Sponge for Chronic Allergic Rhinitis: Randomized Clinical Trial

We compared the results of this more convenient and less irritating method with those of other therapeutic modalities, such as BTA injection, and found that BTA (Dysport) may be used safely and effectively in selected patients with CAR, who had been treated with conventional medications with no clinical improvement and who still felt unwell. The major limitation of this therapeutic approach is the high cost of the BTA medication. Further research in different geographic regions is recommended.